No Risk of Guillain-Barre Syndrome from HPV Vaccine
Researchers say there is no risk of Guillain-Barré Syndrome following HPV vaccine. Though HPV vaccine has not be linked to the disease, recommendations to continue monitoring for new cases of Guillain-Barré Syndrome within six weeks of HPV vaccine will be presented at the American Academy of Neurology's 61st Annual Meeting in Seattle, April 25 to May 2, 2009.
Guillain-Barré Syndrome occurs following infection, and can be life threatening, though most people recover uneventfully. Symptoms include muscle weakness and tingling. Guillain-Barré Syndrome can sometimes progress to paralysis. A small number of reports of Guillain-Barré Syndrome have been reported following HPV vaccine.
Researchers analyzed data from the CDC, extracting reports of Guillain-Barré Syndrome among young women who received HPV vaccine between 2006 and 2008 in the United States, using the CDC's Vaccine Adverse Event Reporting System.
Of the sixteen million HPV vaccine distributed since 2006, only 36 cases of Guillain-Barré Syndrome have been reported. Guillain-Barré Syndrome occurred within six weeks of receiving HPV vaccine, in 75% of cases. Forty percent of the group reporting Guillain-Barré Syndrome after receiving HPV had also received additional vaccines, while sixty percent had received HPV vaccine only before the onset of Guillain-Barré Syndrome.
The researchers concluded the incidence of Guillain-Barré Syndrome following HPV vaccine is no greater than in the general population, though they recommend continued close monitoring.
Nizar Souayah, MD, of the University of Medicine and Dentistry of New Jersey in Newark and a member of the American Academy of Neurology says … "the fact that most of these cases occurred within six weeks of vaccination does warrant careful monitoring for any additional cases and continued analysis."
Guillain-Barré Syndrome is a disease that occurs when a person's own immune system attacks the peripheral nervous system, usually following infection.
The study showed no risk of Guillain-Barré Syndrome following HPV vaccine. However, the American Academy of Neurology advises that continued monitoring is needed.